Quick Answer
IDEXX LABORATORIES INC /DE reported Total Revenue of $4.30 billion for fiscal year 2025.
IDEXX LABORATORIES INC /DE — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.30B +10.4% |
$3.90B +6.5% |
$3.66B +8.7% |
$3.37B +4.7% |
$3.22B +18.8% |
$2.71B +12.5% |
| Revenue (ASC 606) | $4.30B +10.4% |
$3.90B +6.5% |
$3.66B +8.7% |
$3.37B +4.7% |
$3.22B +18.8% |
$2.71B +12.5% |
| Net Income | $1.06B +19.3% |
$887.87M +5.1% |
$845.04M +24.4% |
$679.09M -8.8% |
$744.85M +28.0% |
$581.78M +36.0% |
| Diluted EPS | $13.08 +22.6% |
$10.67 +6.1% |
$10.06 +25.3% |
$8.03 -6.6% |
$8.60 +28.2% |
$6.71 +37.2% |
| Total Assets | $3.35B +1.7% |
$3.29B +1.0% |
$3.26B +18.7% |
$2.75B +12.7% |
$2.44B +6.2% |
$2.29B +25.2% |
| Cash and Equivalents | $180.07M -37.5% |
$288.27M -36.5% |
$453.93M +303.3% |
$112.55M -22.1% |
$144.45M -62.4% |
$383.93M +325.0% |
| Long-Term Debt | $374.84M -16.7% |
$449.79M -27.8% |
$622.88M -10.3% |
$694.39M -10.4% |
$775.21M -9.7% |
$858.49M +22.8% |
| Stockholders Equity | $1.61B +0.6% |
$1.60B +7.5% |
$1.48B +143.9% |
$608.74M -11.8% |
$689.99M +9.2% |
$632.09M +256.2% |
| R&D Expense | $251.21M +14.3% |
$219.79M +15.1% |
$190.95M -25.1% |
$254.82M +58.3% |
$161.01M +14.0% |
$141.25M +6.0% |
| Operating Income | $1.36B +20.5% |
$1.13B +2.8% |
$1.10B +22.1% |
$898.76M -3.6% |
$932.03M +34.2% |
$694.52M +25.6% |
| Gross Profit | $2.66B +11.8% |
$2.38B +8.6% |
$2.19B +9.3% |
$2.00B +6.1% |
$1.89B +20.3% |
$1.57B +15.0% |
| Shares Outstanding | 79.71M -2.3% |
81.60M -1.7% |
83.03M +0.2% |
82.89M -2.0% |
84.56M -1.0% |
85.45M -0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.11B | +13.3% | -0.4% |
| Revenue (ASC 606) | September 30, 2025 | $1.11B | +13.3% | -0.4% |
| Net Income | September 30, 2025 | $274.61M | +17.9% | -6.6% |
| Diluted EPS | September 30, 2025 | $3.40 | +21.4% | -6.3% |
| Total Assets | September 30, 2025 | $3.39B | +1.1% | +1.7% |
| Cash and Equivalents | September 30, 2025 | $208.17M | -32.6% | +26.5% |
| Long-Term Debt | September 30, 2025 | $374.82M | -28.6% | -16.7% |
| Stockholders Equity | September 30, 2025 | $1.56B | -3.5% | +7.0% |
| R&D Expense | September 30, 2025 | $63.41M | +17.5% | +2.5% |
| Operating Income | September 30, 2025 | $354.85M | +16.8% | -4.9% |
| Gross Profit | September 30, 2025 | $683.35M | +14.6% | -1.6% |
| Shares Outstanding | September 30, 2025 | 80.00M | -2.5% | -0.2% |
- IDEXX LABORATORIES INC /DE reported Total Revenue of $4.30 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +10.4% in Total Revenue compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Revenue (ASC 606) of $4.30 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +10.4% in Revenue (ASC 606) compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Net Income of $1.06 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +19.3% in Net Income compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Diluted EPS of $13.08 per share for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +22.6% in Diluted EPS compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Total Assets of $3.35 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +1.7% in Total Assets compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Cash and Equivalents of $180.07 million for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed a decrease of -37.5% in Cash and Equivalents compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Long-Term Debt of $374.84 million for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed a decrease of -16.7% in Long-Term Debt compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Stockholders Equity of $1.61 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +0.6% in Stockholders Equity compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported R&D Expense of $251.21 million for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +14.3% in R&D Expense compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Operating Income of $1.36 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +20.5% in Operating Income compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Gross Profit of $2.66 billion for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed an increase of +11.8% in Gross Profit compared to the prior fiscal year.
- IDEXX LABORATORIES INC /DE reported Shares Outstanding of 79.71 million shares for fiscal year 2025.
- IDEXX LABORATORIES INC /DE showed a decrease of -2.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: